A novel K-ras mutation in colorectal cancer. A case report and literature review

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3369-3374

  Palmirotta, Raffaele ^a   Savonarola, Annalisa ^a   Formica, Vincenzo ^b   Ludovici, Giorgia ^a   Del Monte, Girolamo ^c   Roselli, Mario ^b   Guadagni, Fiorella ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c San Raffaele Rocca di Papa Clinical Center   (Italy)

Author keywords

Colorectal cancer; K ras; Panitumumab

Indexed keywords

B RAF KINASE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PROTEIN P53;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CASE REPORT; CODON; COLORECTAL CANCER; DNA EXTRACTION; DNA SEQUENCE; EXON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MICRODISSECTION; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PATIENT IDENTIFICATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

ADENOCARCINOMA, MUCINOUS; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 68549090700     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
3. Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684, 1998.
4. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297, 1987.
5. Martinez-Garza SG, Nunez-Salazar A, Calderon-Garciduenas AL, Bosques-Padilla FJ, Niderhauser-Garcia A and Banera-Saldana HA: Frequency and clinicopathology associations of K-ras mutations in colorectal cancer in a northeast Mexican population. Dig Dis 17: 225-229, 1999. (Pubitemid 30198256)
6. Urosevic N, Krtolica K, Skaro-Milic A, Knezevic-Usaj S and Dujic A: Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. Int J Cancer 54: 249-254, 1993. (Pubitemid 23154890)
7. Breivik J, Meling GI, Spurkland A, Rognum TO and Gaudernack G: K-ras mutation in colorectal cancer: relations to patient age, sex and tumor location. Br J Cancer 69: 367-371, 1994. (Pubitemid 24046565)
8. Bos JL: Ras oncogenes in human cancer: a review. [published erratum appears in Cancer Res. 1990; 50: 1352]. Cancer Res 49: 4682-4689, 1989.
9. Baisse B, Bouzourene H, Saraga EP, Bosman FT and Benhattar J: Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 93: 346-352, 2001. (Pubitemid 32592052)
10. Hughes R, Cross AJ, Pollock JR and Bingham S: Dose-dependent effect of dietary meat on endogenous colonic N-nitrosation. Carcinogenesis 22: 199-202, 2001. (Pubitemid 32098163)
11. Bingham SA, Pignatelli B, Pollock JR, Ellul A, Malaveille C, Gross G, Runswick S, Cummings JH and O'Neill IK: Does increased endogenous formation of N-nitroso compounds in the human colon explain the association between red meat and colon cancer? Carcinogenesis 17: 515-523, 1996.
12. Beranek M, Bures J, Palicka V, Jandik P, Langr F and Nejedla E: A relationship between K-ras gene mutations and some clinical and histological variables in patients with primary colorectal carcinoma. Clin Chem Lab Med 37: 723-727, 1999. (Pubitemid 29423987)
13. Cerottini JP, Caplin S, Saraga E, Givel JC and Benhattar J: The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 175: 198-202, 1998. (Pubitemid 28173710)
14. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M and Slattery ML: Relationship of Ki-ras mutations in colon cancers to tumor location, stage and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9: 1193-1197, 2000. (Pubitemid 30844068)
15. Moerkerk P, Arends JW, van Driel M, de Bruine A, de Goeij A and ten Kate J: Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 54: 3376-3378, 1994. (Pubitemid 24225952)
16. Span M, Moerkerk PT, De Goeij AF and Arends JW: A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 69: 241-245, 1996. (Pubitemid 26233305)
17. Kampman E, Voskuil DW, van Kraats AA, Balder HF, van Muijen GN, Goldbohm RA and van't Veer P: Animal products and K-ras codon 12 and 13 mutations in colon carcinomas. Carcinogenesis 21: 307-309, 2000. (Pubitemid 30098718)
18. Brink M, de Goeij AFPM, Weijenberg MP, Roemen GMJM, Lentjes MHFM, Pachen MMM, Smits KM, de Bruine AP, Goldbohm RA and van den Brandt PA: K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands Cohort Study. Carcinogenesis 24(4): 703-710, 2003. (Pubitemid 36592405)
19. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD and Chang DD: Wild-type K-RAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
20. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F and Laurent-Puig P: K-RAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008. (Pubitemid 351171687)
21. Rouleau E, Spyratos F, Dieumegard B, Guinebretière JM, Lidereau R and Bièche I: K-RAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition. Br J Cancer 99(12): 2100, 2008.
22. Akagi K, Uchibori R, Yamaguchi K, Kurosawa K, Tanaka Y and Kozu T: Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochem Biophys Res Commun 352: 728-732, 2007. (Pubitemid 44880315)
23. Lin SR, Tsai JH, Yang YC and Lee SC: Mutations of K-ras oncogene in human adrenal tumors in Taiwan. Br J Cancer 77: 1060-1065, 1998. (Pubitemid 28116275)
24. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR and Futreal PA: Recurrent K-RAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5(8): 928-932, 2006. (Pubitemid 44776510)
25. Wójcik P, Kulig J, Okoń K, Zazula M, Moździoch I, Niepsuj A and Stachura J: K-RAS mutation profile in colorectal carcinoma and novel mutation-internal tandem duplication in K-RAS. Pol J Pathol 59(2): 93-96, 2008. (Pubitemid 352029608)
26. Tsukuda K, Tanino M, Soga H, Shimizu N and Shimizu K: A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun 278: 653-658, 2000.
27. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY: Similarity of the phenotypic patterns associated with BRAF and K-RAS mutations in colorectal neoplasia. Cancer Res 62(22): 6451-6455, 2002. (Pubitemid 35364105)
28. Miyakura Y, Sugano K, Fukayama N, Konishi F and Nagai H: Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer. Jpn J Clin Oncol 32(6): 219-221, 2002. (Pubitemid 41289001)
29. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G and Ensari A: K-RAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453(5): 417-423, 2008
30. Palmirotta R, Matera S, Curia MC, Aceto G, el Zhobi B, Verginelli F, Guadagni F, Casale V, Stigliano V, Messerini L, Mariani-Costantini R, Battista P and Cama A: Correlations between phenotype and microsatellite instability in HNPCC: implications for genetic testing. Fam Cancer 3(2): 117-121, 2004.
31. Catalano T, Curia MC, Aceto G, Verginelli F, Cascinu S, Cama A, Mariani-Costantini R, Teti D and Battista P: Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. Oncol Rep 14: 625-631, 2005.
32. Ottini L, Falchetti M, D'Amico C, Amorosi A, Saieva C, Masala G, Frati L, Cama A, Palli D and Mariani-Costantini R: Mutations at coding mononucleotide repeats in gastric cancer with the microsatellite mutator phenotype. Oncogene 16(21): 2767-2772, 1998. (Pubitemid 28279342)
33. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S and Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35): 5705-5712, 2008.
34. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M and Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13): 1658-1664, 2007. (Pubitemid 46797944)
35. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F Zanon C, Moroni M, Veronese S, Siena S and Bardelli A: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648, 2007. (Pubitemid 46548951)
36. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F and Laurent-Puig P: K-RAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
37. Wang YC, Lee HS, Chen SK, Yang SC and Chen CY: Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome. Cancer Res Clin Oncol 124: 517-522, 1998.
38. Vachtenheim J, Horáková I, Novotná H, Opáalka P and Roubková H: Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Clin Cancer Res 1: 359-365, 1995.
39. Dexter DL and Leith JT: Tumor heterogeneity and drug resistance. J Clin Oncol 4(2): 244-257, 1986.
40. Sweeney C, Boucher KM, Samowitz WS, Wolff RK, Albertsen H, Curtin K, Caan BJ and Slattery ML: Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes Chromosomes Cancer 48(1): 1-9, 2009.
41. Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K, Takeda M, Kominami K, Iishii T, Tanaka N and Matsubara N: No duplicate K-RAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple K-RAS mutations. J Int Med Res 35(4): 450-457, 2007. (Pubitemid 47261106)
42. Yan J, Roy S, Apolloni A, Lane A and Hancock JF: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 273: 24052-24056, 1998. (Pubitemid 28435747)
43. Zhang BH, Guan KL: Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19: 5429-5439, 2000.
44. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF and Bast RC Jr; ASCO: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327, 2006.